MONDAY, May 8, 2023 (HealthDay News) — The U.S. federal government has committed $5 million to study three existing and planned safe drug injection sites to see if they help prevent overdoses and whether they may offer savings in the health and criminal justice systems.
At these overdose prevention centers (OPCs), people can use heroin or other illegal drugs under supervision so they can potentially be revived if they overdose. The funding would not pay to operate the sites, but to study two now open in New York City and a third that is opening next year in Providence, Rhode Island. Researchers from New York University and Brown University expect to enroll about 1,000 adult drug users.
“We have an unprecedented opportunity to study the first publicly recognized overdose prevention centers in the country across two different states, as well as the impact on the communities in which they operate,” said Magdalena Cerdá, director of the NYU Langone Center for Opioid Epidemiology and Policy and one of the study’s lead investigators, said in an NYU news release. “This research is urgently needed to inform policies that can best support public health, as more jurisdictions across the country consider implementing OPCs.”
These sites can be controversial, with some worrying they will do damage to surrounding neighborhoods and encourage drug use. Supporters say they can save lives and help people find addiction treatment and other medical services, the Associated Press reported.
“There is a lot of discussion about overdose prevention centers, but ultimately, we need data to see if they are working or not, and what impact they may have on the community,” said Nora Volkow, M.D., director of the National Institute on Drug Abuse, which awarded the grant.
Existing injection sites operate in 14 countries, including Canada, Australia, and France. New York City opened the first publicly known U.S. site in 2021. It is possible they will grow to include other U.S. states, but bills allowing them were vetoed last year by governors in California and Vermont. The Pennsylvania Senate banned them last week, the AP reported.
Copyright © 2023 HealthDay. All rights reserved.
